Skip to main content

Table 4 Comparison of SLEDAI between the two groups

From: The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study

IndicatorCancer group (n = 51) (positive/total, percentage)Control group (n = 204) (positive/total, percentage)P value
Low C316/36, 44.44%74/90, 82.22%< 0.01
Low C414/36, 38.89%48/90, 53.33%0.17
Low WBC6/48, 12.50%26/102, 25.49%0.09
Low PLT10/48, 20.83%34/102, 33.33%0.13
Proteinuria6/49, 12.24%36/100, 36.00%< 0.01
SLEDAI, median28< 0.01
  1. WBC white blood cell, PLT platelet, SLEDAI SLE Disease Activity Index